Add to ORKGTime to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drug
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-re...
During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially c...
BACKGROUND: The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENE...
Background: It is currently unknown whether early immunomodulatory treatment in relapsing-remitting ...
Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting ...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
Multiple sclerosis (MS) is a chronic demyelinating disease of young employable people. Demyelination...
Early prescription of disease-modifying treatment was shown to improve the long-term prognosis in mu...
The course of multiple sclerosis (MS) is extremely variable. A limited number of demographic and cli...
International audienceIn multiple sclerosis, treatment start or switch is prompted by evidence of di...
This presentation will focus on imrnunomodulatory drUgs that have become available for multiple scle...
Objective To investigate factors associated with the risk of secondary progression in relapsing-remi...
In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst...
Multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system characte...
Multiple sclerosis is a progressive inflammatory disease of the central nervous system. With prevent...
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-re...
During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially c...
BACKGROUND: The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENE...
Background: It is currently unknown whether early immunomodulatory treatment in relapsing-remitting ...
Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting ...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
Multiple sclerosis (MS) is a chronic demyelinating disease of young employable people. Demyelination...
Early prescription of disease-modifying treatment was shown to improve the long-term prognosis in mu...
The course of multiple sclerosis (MS) is extremely variable. A limited number of demographic and cli...
International audienceIn multiple sclerosis, treatment start or switch is prompted by evidence of di...
This presentation will focus on imrnunomodulatory drUgs that have become available for multiple scle...
Objective To investigate factors associated with the risk of secondary progression in relapsing-remi...
In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst...
Multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system characte...
Multiple sclerosis is a progressive inflammatory disease of the central nervous system. With prevent...
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-re...
During the 20 past years, the management of multiple sclerosis (MS) has largely changed especially c...
BACKGROUND: The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENE...